top of page
Home / Theragnostics / Lu-177 Inca
Lu-177 nca
Lutetium-177 (Lu-177) is increasingly recognized as a highly promising radionuclide for targeted therapy and is gaining attention as a groundbreaking theranostic isotope for treating neuroendocrine tumors and metastatic castration-resistant prostate cancer (mCRPC). Additionally, ongoing developments are exploring its potential in new carrier molecules designed for precise tumor targeting.
Extensive clinical trials have shown that Lu-177 therapies effectively enhance patients' quality of life and extend progression-free survival for these conditions.
We supply Lu-177 no-carrier-added (NCA). Please contact us to check availability for your specific market.
bottom of page